Skip to main content
Clinical Trials/NCT04010994
NCT04010994
Unknown
Phase 1

Treatment of Patients With Optic Nerve Damage Patients Using Electrostimulation: a Home Stimulation Study

University of Magdeburg1 site in 1 country50 target enrollmentAugust 5, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Glaucoma
Sponsor
University of Magdeburg
Enrollment
50
Locations
1
Primary Endpoint
Visual field size
Last Updated
6 years ago

Overview

Brief Summary

The aim of the present study is to investigate the possibilities of visual field enhancement with electrical stimulation (ES) as a home stimulation method, in a total of 50 patients with optical neuropathy, who have already been treated with ES in the past.

Furthermore, factors responsible for response variability and treatment effectiveness are also explored: (i) the role of mental stress (or stress resilience), (ii) the status of biomarkers, such as the systemic stress hormone levels and blood supply to the eye and brain (specifically vascular dysregulation) and (iii) the influence of personality, anxiety, depression and lifestyle. The study serves to further validate this ES procedure for the treatment of visual impairment. Specifically, better efficacy, better compliance, lowest response variability are expected after long-term home use.

Registry
clinicaltrials.gov
Start Date
August 5, 2019
End Date
December 31, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University of Magdeburg
Responsible Party
Principal Investigator
Principal Investigator

Bernhard A. Sabel

Head of Institute, Professor

University of Magdeburg

Eligibility Criteria

Inclusion Criteria

  • Patients with glaucoma, disease duration at least 6 months
  • stable visual field defect across baseline measurement (subjects with spontaneous fluctuations and recovery of vision excluded)
  • presence of residual vision and detectable gradual transition between the intact and the absolutely blind part of the visual field according to evaluation of the clinician
  • best corrected visual acuity at least 0.4 (20/50 Snellen) or better

Exclusion Criteria

  • autoimmune diseases in the acute stage
  • neurological and mental diseases
  • diabetic retinopathy
  • addictions
  • hypertension (maximum 160/100 mmHg)
  • retinitis pigmentosa-
  • pathological nystagmus
  • non-distant tumors or recurrent tumors
  • photosensitivity
  • pregnancy

Outcomes

Primary Outcomes

Visual field size

Time Frame: 3 months

Static perimetry and high resolution perimetry will be used to measure the visual field sizes

Secondary Outcomes

  • EEG connectivities in the visual system(3 months)
  • Level of vascular regulation/dysregulation in the eye(3 months)

Study Sites (1)

Loading locations...

Similar Trials